ArticlePloS one2026
Trends of laboratory nonhuman primate licensing in China between 2020 and 2024: A national database analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonhuman primates are critical translational models in biomedical research due to their genetic, anatomical, and physiological similarities to humans. China, once a dominant global supplier of captive-bred laboratory primates, has long maintained a national licensure system to govern their production and use. Despite this, the overall scope, spatial distribution, and institutional landscape of licensing activities for laboratory primates in China remain insufficiently characterized, limiting data-driven governance and resource planning. This study conducted a comprehensive retrospective analysis of all laboratory primate licenses issued in China between 2020 and 2024, based on data retrieved from the China Laboratory Animal Licensing Management System (LALMS). In total, 430 licenses were analyzed across production and utilization categories, temporal dynamics, geographical distribution, and institutional ownership. Utilization licenses constituted 85% of the total, while production licenses accounted for 15%. Licensing activity expanded progressively until 2023 before declining sharply in 2024. Among 31 provincial-level administrative divisions in mainland China, 28 were authorized to produce or utilize laboratory primates. Beijing and Jiangsu emerged as primary centers of licensing activity, particularly for utilization. In contrast, production licenses were predominantly concentrated in Guangxi and Yunnan. Utilization licenses exhibited broader geographic distribution than production licenses, although licensing activity was heavily concentrated in East China (31%), North China (22%), and South China (19%). The majority of licenses were held by commercial enterprises (60%), followed by universities (22%) and research institutes (18%). These findings define the temporal and spatial landscape of laboratory primate licensing in China and generate critical data to inform resource allocation, improve regulatory transparency, and promote the responsible and sustainable integration of primate models into biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.